Evidence map›Paper›PMID 42656847›Full record

ArticleGenetics in medicine open2026

Germline

Aasem Abu Shtaya, Shahar Aloni, Marina Eskin-Schwartz, Nethanel Asher, Noy Azulay, Lina Basel-Salmon, Lily Bazak, Rinat Bernstein Molho, Liza Douiev, Sarit Farage Barhom and 22 more

Abstract read
In one paragraph

Article in Genetics in medicine open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Aasem Abu ShtayaRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
Shahar AloniRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
Marina Eskin-SchwartzGenetics Institute, Soroka University Medical Center, Beer Sheva, Israel.
Nethanel AsherMelanoma and Skin Cancer Center at the Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.
Noy AzulayRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
Lina Basel-SalmonRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
Lily BazakRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
Rinat Bernstein MolhoGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Liza DouievDepartment of Genetics, Hadassah Medical Center, Jerusalem, Israel.
Sarit Farage BarhomRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
Eitan FriedmanGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Ofer IsakovGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Ahmad MahamidDivision of Surgery, Carmel Medical Center, Haifa, Israel.
Orli MichaeliPediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Inbal KedarRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
Zohar LeviGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Sari LibermanMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Shikma MordechaiGenetic Unit, Ziv Medical Center, Safed, Israel.
Ofer ReiterGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Gili Reznick LeviThe Genetics Institute, Rambam Health Care Campus, Haifa, Israel.
Shiri Shkedi RafidDepartment of Genetics, Hadassah Medical Center, Jerusalem, Israel.
Zinab SarsorThe Felsenstein Medical Research Center, Petah Tikva, Israel.
Orit UzielGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Sharon SimchoniThe Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Tom WalshDepartment of Medicine, University of Washington, Seattle, WA.
Ofir WolachGray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Ori SegolUnit of Gastroenterology, Lady Davis Carmel Medical Center, Haifa, Israel.
Tamar Yablonski-PeretzFaculty of Medicine, Hebrew University, Jerusalem, Israel.
Aviad ZickFaculty of Medicine, Hebrew University, Jerusalem, Israel.
Avinoam GluckDepartment of Genetics, The Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Yehuda TzfatiDepartment of Genetics, The Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Yael GoldbergRecanati Genetics Institute, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to expand the clinical and biological understanding of Methods: We conducted a retrospective analysis of 44 individuals carrying pathogenic or likely pathogenic Results: Of 44 heterozygotes, 31 had the c.233T>C; p.(Ile78Thr) variant, 8 had c.1672dup; p.(Tyr558Leufs∗6), and 5 had other frameshifting, likely loss-of-function variants. Cancer was diagnosed in 27 heterozygotes (61%), totaling 84 primary malignancies (range: 0-8 per person), with most cases (79%) occurring after the age of 50 years. Melanoma (34%) and breast cancer in females (45%) were the most common. Additional tumors included papillary thyroid carcinoma, desmoid tumors, and diverse malignant and benign neoplasms. Colonic polyps were frequent. Conclusion:

Indexed as

Cancer predisposition syndromeFounder variantMelanomaPOT1Telomere

Identifiers

PMID42656847
PMCPMC13507739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.